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Aida Malovic, MSc, Alexandra Russell, BSc (Hons), Alice Rose, BSc (Hons),
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Background: There is a growing interest in using group
cognitive–behavioral therapy (CBT) with people who have
Asperger syndrome (AS) and comorbid mental health
problems. This study aims to assess the cost-effectiveness
of modified group CBT for adults with AS experiencing
co-occurring anxiety compared to treatment-as-usual.
Methods: Economic evaluation alongside a pilot, multi-
center, single-blind, randomized controlled crossover trial.
Costs from the UK public sector (National Health Service
and Social Services) and societal perspectives, quality-
adjusted life years (QALYs), incremental net (monetary)
benefit (INB), expected value of perfect information,
expected value of sample information, expected net gain
of sampling, and efficient sample size of a future trial are
reported. Results: Over 48 weeks, from the societal per-
spective, CBT results in additional costs of £6,647, with
only a 0.015 incremental gain in QALYs, leading to a neg-
ative INB estimate of £6,206 and a 23% probability of
cost-effectiveness at a threshold of £30,000/QALY. Results
from sensitivity analyses support the unlikely cost-
effectiveness of CBT but indicate the potential for cost-
effectiveness over longer time horizons. Eliminating
decision uncertainty is valued at £277 million, and the
efficient sample size for a future trial is estimated at
1,200 participants per arm. Limitations: Relatively small
sample size and prevalence of missing data present chal-
lenges to the interpretation of the results. Conclusions:
Current evidence from this small pilot study suggests that,
on average, modified group CBT is not cost-effective.
However, there is much decision uncertainty so such a
conclusion could be wrong. A large, full-scale trial to
reduce uncertainty would be an efficient investment for
the UK health economy. Key words: autism spectrum
disorder; cost-effectiveness analysis; psychiatric
disorders; value of information. (MDM Policy & Practice
20XX; XX: 000–000)
Cognitive–behavioral therapy (CBT) that specifi-cally targets anxiety symptoms in children with
Asperger syndrome (AS) has been designed and
shown to be effective,1 but limited evidence exists
concerning its effectiveness in adults.2 Furthermore,
there are no data on the cost-effectiveness of CBT in
an adult AS population. To address these concerns,
the People with Asperger Syndrome and Anxiety
disorders (PAsSA) treatment trial was conducted: a
pilot, multicenter, single-blind, randomized con-
trolled crossover trial of modified group CBT com-
pared to a wait-list control arm receiving treatment-
as-usual (TAU) in adults with AS experiencing clini-
cally significant anxiety.3,4
CBT offers a highly structured approach, where
treatment goals and interventions are planned and
undertaken in a gradual manner, making it suitable
for AS patients who usually find it hard to tolerate
surprise or uncertainty in their care. High rates of
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comorbid anxiety in AS patients are reported,5–8
and due to the lack of evidence of (cost-) effective
nonpharmacological interventions, patients may
not be offered formal help or may be given subopti-
mal treatments, potentially increasing the burden
on health and social services that care for AS
patients.
Following good research practices for cost-
effectiveness analysis alongside clinical trials,9 the
results of an economic evaluation based on the
PAsSA trial are presented to help inform resource
allocation decision making. The cost-effectiveness
of modified group CBT compared to TAU in adult
patients with AS experiencing clinically significant
anxiety is estimated from both the perspective of
the UK public sector (defined as National Health
Service and Social Services; NHS-SS) and society
(defined as NHS-SS, other public and voluntary ser-
vices, out-of-pocket expenditure, and lost produc-
tivity) over a 24- and 48-week time horizon. The
expected return on investment to UK society from a
future full-scale trial is also determined.
METHODS
Overview of the Trial
Full details of the PAsSA trial study protocol and
its clinical findings are reported elsewhere.3,4
Briefly, 52 adults from communities in the south
and east of the United Kingdom, between 16 and 65
years of age, fulfilling diagnostic criteria for AS,
high functioning autism, or pervasive development
disorder–not otherwise specified, and in whom a
diagnosis of anxiety was confirmed when assessing
their eligibility for the trial were randomized to a
CBT treatment arm or a wait-list TAU control arm
and crossed over after 24 weeks of CBT treatment.
Participants in the treatment arm received three
initial sessions of 1:1 CBT, followed by 21 group
CBT sessions during the first 24 weeks of the trial.
Upon crossover at week 24, participants initially
randomized to TAU also received the CBT regimen
during weeks 24 to 48 of the trial. All participants
received TAU for the entire duration of the trial
(i.e., both before and after crossover), comprising
normal NHS access to primary care, which would
have included medication, potentially counselling,
and some were receiving mental health care in sec-
ondary care, excluding CBT (none of the partici-
pants reported having concurrent CBT, but some
had received such treatment in the past). A favor-
able ethical opinion for the trial was obtained from
the Cambridgeshire 4 NHS Research Ethics
Committee (Reference: 10/H0305/42).
Overview of the Economic Evaluation
While crossover trials are valuable in encoura-
ging enrolment into a trial, they are problematic for
economic evaluations due to the lack of a washout
period (indeed, it is hoped that the treatment
effect will continue after the intervention period).
Therefore, we analyze the results of CBT versus
TAU over a 24-week within-trial period from both
the perspectives of the UK NHS-SS and society. The
cost-effectiveness over a 48-week (~1 year) time hor-
izon is also explored through follow-up data
observed in the CBT arm and extrapolation of
TAU data. Results are presented using two generic
preference-based measures of health-related quality
of life (EQ-5D-3L and SF-6D) and using both a
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complete case analysis (i.e., all participants with
incomplete data removed from the analysis) and a
multiple imputation analysis, adjusted for baseline
utility and costs.
To avoid misleading conclusions as a result of
cost shifting between budgets rather than genuine
changes in resource consumption, it is argued that
the most appropriate analytic perspective should be
that of society.10 The National Institute for Health
and Care Excellence (NICE) in England prefers
health effects in adults are measured and valued
using the EQ-5D and that time horizons are long
enough to reflect all important differences in costs
or outcomes between the interventions being com-
pared.11 Finally, accounting for baseline values
takes into account any differences in patient charac-
teristics at baseline12 and multiple imputation
avoids discarding informative data.13 Therefore, the
imputed and adjusted, 48-week, EQ-5D-3L cost-
utility analysis conducted from the societal per-
spective was selected as the primary analysis. In
addition, areas of uncertainty are explored and the
value of future research to UK society is quantified
to determine if a larger, definitive trial is worth-
while to reduce decision uncertainty.
Resource Use and Costs
Health (secondary and primary care services for
both the patient and family members as well as
medications) and social services (community care,
respite, and voluntary organization services as well
as day activities) use, patient/family out-of-pocket
costs, informal care by family members, and the
value of any lost productivity to society by carers
were collected using an adapted version of the Client
Socio-Demographic and Service Receipt Inventory.14
Data collected at baseline pertained to the 3 months
prior to randomization, which were then used as a
predictor of future costs in the analysis. Resource
data were divided into six categories: NHS, social
services, other public services, voluntary/charity ser-
vices, out-of-pocket expenses, and lost productivity.
Costs involved in delivering the intervention (i.e.,
conducting the 1:1 and group-based sessions over the
24-week treatment period) were derived from the Unit
Costs of Health and Social Care15 and were based on
the cost of three 55-minute 1:1 CBT sessions plus the
cost per participant per 1-hour session for 22 sessions
of group CBT assuming 12 people per session.
Cost per patient was calculated by multiplying
unit costs identified from standard reference sources
(Table S1) by resource quantities (Table S2). Inpatient
hospital visits were costed using the National
Schedule of Reference Costs.16 Prescriptions were
assigned appropriate prices from the British National
Formulary.17 Unit costs for other resource use counts
were mainly derived from the Unit Costs of Health
and Social Care.15 All costs are expressed in 2014
British Pounds Sterling. No discounting was used in
the 24-week within-trial or 48-week extrapolation
analyses as the follow-up periods were less than 1
year. However, costs and quality-adjusted life years
(QALYs) in the 48- to 72-week extrapolation period
used in sensitivity analyses were discounted by 3.5%
as per NICE guidelines.11
Utility Measurement and Valuation
Utility values were measured at baseline, 24
weeks, and 48 weeks. Although the EQ-5D-3L was
identified as the primary utility measure for the eco-
nomic evaluation (as per NICE guidelines),11 for
comparative purposes SF-6D utility values (derived
from the SF-36 UK version 1)18 were also collected
on each patient over time for use in sensitivity anal-
ysis. Both have been shown to be valid for use in
common mental health problems such as anxiety
and show some evidence of responsiveness to
change in health status.19 The UK tariffs for both
instruments were used to derive the utility val-
ues.18,20 QALYs were calculated as the area under
the utility curve for each patient.21
Imputation Model for Missing Data
Missing cost or quality-of-life data were esti-
mated using multiple imputation (MI) implemented
separately by treatment allocation.13 Imputations
were performed at the level of total costs and health
state utility values for baseline and the two follow-
up points. The use of log MI with predictive mean
matching (PMM) has been shown to result in reli-
able results with large amounts of missing data and
also performs well for data with a large amount of
zero values.22 Therefore, this was selected as the
MI strategy for the total cost variables. Before log-
transformation a constant was added to zeros in the
data, which was subtracted again following imputa-
tion and re-transformation.
Health state utilities were not transformed prior to
imputation and only the follow-up values required
imputation using PMM. Covariates included in the
imputation model were health state utility values for
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the EQ-5D-3L and SF-6D at 24 and 48 weeks; base-
line, 24-, and 48-week NHS-SS and social costs; age;
and highest education level. Five imputed data sets
were obtained using chained equations (MI-MICE) in
STATA/IC version 14.0 (see the statistical analyses
section for more details). Five imputed data sets
were chosen as even with 50% missing data, esti-
mates from multiple imputation based on five
imputations only have a standard deviation that is
about 5% wider than one based on infinite imputa-
tions.23 After imputation, the complete data were
transformed back to their original scale prior to
any analyses.
Extrapolation Methods
The PAsSA trial used a crossover design and
therefore the longest any patient received CBT
was 24 weeks. In order to determine the cost-
effectiveness of a 24-week course of CBT over a 1-
year time horizon, extrapolation of the within-trial
analysis was required. A detailed schematic of the
crossover and extrapolation methods is provided in
Figure 1. For patients initially randomized to CBT,
costs and QALYs from weeks 24 to 48 were added to
the initial 24-week data to establish an approximate
1-year time horizon. Note that these patients only
received CBT during the initial 24-week period. For
patients initially randomized to TAU their costs and
QALYs were assumed to be the same over weeks 24
to 48 as during the initial 24 weeks before crossover.
The PAsSA trial protocol3 proposed that trial
data would be extrapolated to a 5-year time horizon.
Due to the amount of missing data and resultant
small sample size, it was deemed inappropriate to
extrapolate any trial findings this far into the future.
The extrapolation for the main analyses was there-
fore limited to only 48 weeks so that minimal
assumptions could be made but at the same time
the cost-effectiveness of CBT beyond the within-
trial period (i.e., 24 weeks) could be explored.
Extrapolation of the time horizon to 72 weeks was
also tested in sensitivity analyses by carrying for-
ward the costs and QALYs from weeks 24 to 48 for
the CBT arm for an additional 24 weeks. Costs and
QALYs for TAU patients were assumed to be the
Figure 1 Schematic of the trial crossover and extrapolation methods. For patients initially randomized to CBT, costs and QALYs from
weeks 24 to 48 were added to the initial 24-week data to establish an approximate 1-year time horizon. Note that patients only received
CBT during the initial 24-week period. For patients initially randomized to TAU their costs and QALYs were assumed to be the same
over weeks 24 to 48 as during the initial 24 weeks before crossover. Extrapolation of the time horizon to 72 weeks was also tested in sen-
sitivity analyses by carrying forward the costs and QALYs from weeks 24 to 48 for the CBT arm for an additional 24 weeks. Costs and
QALYs for TAU patients were assumed to be the same over weeks 24 to 48 and weeks 48 to 72 as during the initial 24 weeks before
crossover. CBT = cognitive–behavioral therapy; QALY = quality-adjusted life years; TAU = treatment as usual.
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same over weeks 24 to 48 and weeks 48 to 72 as dur-
ing the initial 24 weeks before crossover.
Statistical Analyses: Stochastic and
Methodological Uncertainty
Mean differences in costs and QALYs were esti-
mated for each of the five imputed data sets using
ordinary least squares (OLS) regressions. The models
accounted for both baseline costs and health state
utility values,12 and 1,000 bootstrapped samples
were created for each of the five data sets. The five
bootstrapped samples were then combined to esti-
mate the means of the 5,000 mean differences in
costs and QALYs, using the percentile method to
estimate 95% confidence intervals (CIs). To avoid
the difficulties associated with interpretation of con-
fidence intervals for incremental cost-effectiveness
ratios (ICERs) that cross quadrants of the cost-
effectiveness plane,24 incremental net (monetary)
benefit (INB)25 was chosen as the main outcome of
the analysis. The willingness-to-pay (WTP) threshold
for estimating the point estimates of INB was set at
£30,000 as this is the upper limit set by NICE for
cost-effective interventions.11 Cost-effectiveness
acceptability curves were calculated by determining
the proportion of INB point estimates that were
greater than zero from the bootstrapped samples for a
range of WTP values.
To address methodological uncertainty a number
of sensitivity analyses were conducted, including
different cost perspectives (public sector [NHS-SS]
vs. societal), different instruments for measuring
health state utility values (EQ-5D-3L vs. SF-6D),
extrapolation of the time horizon to 48 and 72
weeks, and combining cost and health state utility
data for all patients receiving CBT regardless of the
time period. Baseline to 24-week data of the group
initially receiving CBT was combined with 24- to
48-week data of the group initially receiving TAU to
leverage all possible information on participants
receiving the intervention.
Value of Information Analyses
Per-person expected value of perfect information
(EVPI) was estimated both parametrically26 and
nonparametrically24 to confirm equivalence. If
equivalent, this suggests that a parametric approach
to estimating the expected value of sample informa-
tion (EVSI) may yield a reasonable approximation
and therefore save on processing time. Population
EVPI was estimated using a prevalence of 0.98% of
the UK adult population (of the 64.6 million people
in the United Kingdom, 64% are aged 16–64
years)27 being affected by an autism spectrum disor-
der (ASD),28 59% of which have experienced multi-
ple anxiety disorders over their lifetime,5–8 result-
ing in an affected population of 239,501. The time
horizon for CBT to be a relevant intervention was
assumed to be 5 years.
Separate from the main analyses, an OLS regres-
sion of net (monetary) benefit (NB)25 was used to
estimate parameters required for the calculation
of the EVSI using a parametric approach. The
regression was estimated for only the primary anal-
ysis (imputed/adjusted, 48-week, EQ-5D-3L cost-
utility analysis conducted from the societal
perspective). EVSI was estimated by first calculat-
ing the expected reduction in variance of mean
INB from a trial of sample size ns per arm and then
multiplying by the unit normal loss (i.e., the propor-
tion of the INB distribution that is associated with
negative values) and the potentially beneficial popu-
lation (total eligible population less those enrolled in
the study).26 The expected net gain of sampling
(ENGS) for a wide range of sample sizes (ns) was
then estimated by subtracting the cost of sampling
from the EVSI to determine the optimal ns that maxi-
mizes the ENGS. The cost of sampling was estimated
based on the research costs incurred during the con-
duct of the PAsSA trial and categorized by fixed and
variable costs (£218,375/trial and £966/participant
respectively).
RESULTS
Baseline Characteristics of the Study Participants
Fifty-two individuals, with a mean age of 33.1
years, SD 14.6, 54% women, were recruited and
enrolled in the pilot trial. The two treatment arms
(e.g., initial CBT for 24 weeks then crossover to
TAU for 24 weeks and initial TAU for 24 weeks
then crossover to CBT for 24 weeks) were well
matched on IQ, age, and sex. Participants were pre-
dominately white British (96%), single (73%), and
without children (77%). Most participants had at
least a secondary education (96%), with 38% of par-
ticipants holding a university degree. Further
details of the baseline characteristics of the study
participants are provided by Langdon and others.4
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Resource Use and Costs
Point estimate analyses of resource use at both 24
and 48 weeks (Table S2) show very little difference
for the majority of resource use between the CBT
and TAU groups. As this pilot trial is limited in
sample size, it is unclear if these reported differ-
ences are significant, but the relatively high unit
cost of some of these resources (e.g., acute psychotic
crisis admission—£376) could account for a large
portion of the cost difference between the CBT and
TAU groups. From the perspective of the NHS-SS,
on average CBT is associated with an additional
cost of £721 (SE £503) per patient at 24 weeks and
£980 (SE £686) over 48 weeks. Imputed analyses
yield similar results (£673 and £1,028 per patient at
24 and 48 weeks respectively, Table 1).
From the societal perspective, on average CBT
was associated with an additional cost of £1,612 (SE
£4,583) per patient at 24 weeks and £1,365 (SE
£14,515) over 48 weeks (Table 1). When analyzing
the imputed data, the additional per patient costs
associated with CBT were much larger (£10,985 and
£10,997 at 24 and 48 weeks, respectively). These
costs are, however, derived from a small number of
patients and therefore highly uncertain, illustrated
by the associated large standard errors.
Quality of Life and Health State Utilities
Imputed, adjusted analyses yielded a loss of
QALYs for CBT patients compared to TAU patients,
with the exception of the EQ-5D-3L at 48 weeks,
which resulted in a 0.015 gain (Table 2). EQ-5D-3L
and SF-6D QALYs were very similar at 24 weeks,
and the loss of SF-6D QALYs at 48 weeks was simi-
lar to the 24-week period (0.006; Table 2).
Cost Utility and Stochastic Uncertainty
In all analyses, the 95% CIs for INB did not exclude
zero, with the exception of the SF-6D, 24-week cost-
utility analysis from the NHS-SS perspective, which
had a negative 95% CI (Table 2). For all complete case
analyses (CCAs) and imputed/adjusted analyses INB
was consistently negative.
The probability of CBT being more cost-effective
than TAU at a WTP of £30,000 per QALY gained
ranged from 3% to 25% at 24 weeks and from 19%
to 50% over 48 weeks. These probabilities were
smaller for the imputed/adjusted analyses ranging
from 1% to 13% at 24 weeks and 5% to 36% over
48 weeks. In both complete-case and imputed/
adjusted analyses, the 48-week, EQ-5D-3L cost-util-
ity analyses from the NHS-SS perspective had the
highest probability of CBT being more cost-effective
than TAU (Table 2). Figure 2 highlights that the
probability of CBT being cost-effective remains rela-
tively constant from the societal perspective across
different WTP thresholds. In contrast, the probabil-
ity of CBT being cost-effective increases with larger
WTP thresholds from the NHS-SS perspective but
remains below 50%, with the exception of the CCA
at 48 weeks when using the EQ-5D-3L and WTP
thresholds greater than £30,000 per QALY gained.
Methodological Uncertainty
When combining cost and health state utility
data over weeks 24 to 48 from patients who crossed
over to CBT at 24 weeks with data over the first 24
weeks from patients who initially received CBT, the
two analyses from the NHS-SS perspective were
consistent with the original within-trial results. The
results of the two societal analyses were, however,
reported to be more favorable with positive INB esti-
mates in the CCAs, but remained negative in the
imputed/adjusted analyses. This change is the
result of a decrease in the social costs associated
with CBT when using a combined sample treatment
arm (£11,652 vs. £6,157-£6,406; Table S3).
Overall, the results from the 72-week extrapola-
tion were slightly more favorable in terms of cost-
effectiveness (Table S4). INB became positive for
the EQ-5D-3L analyses from the NHS-SS perspec-
tive in both complete case and imputed/adjusted
analyses. INB also became positive for the two analy-
ses from the societal perspective for the CCAs, but
remained negative in the imputed/adjusted analyses.
The probability of CBT being cost-effective at a WTP
of £30,000 also increased for all analyses ranging
from 25% to 58% and 8% to 49% for the complete
case and imputed/adjusted analyses, respectively.
Value of Future Research
Per-person EVPI estimates calculated parametri-
cally and nonparametrically were confirmed to be
equivalent and are reported in Table 2. Relatively
large estimates of value in eliminating decision
uncertainty are observed once converting the per-
person EVPI estimates to population values.
Population EVPI estimates for the CCAs ranged
from £3.1 million to £415 million for the 24-week
period and increased for the 48-week period,
DOBLE AND OTHERS
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48 Weeks) 24 Weeks 48 Weeks
N (24,
48 Weeks) 24 Weeks 48 Weeks
CBT intervention (26, 26) 429.50 (0) 429.50 (0) (26, 26) 0 (0) 0 (0) 429.50 (0) 429.50 (0)
Prescription medicines (25, 25) 38.09 (20.98) 101.53 (40.26) (25, 25) 47.30 (30.60) 94.60 (61.20) 29.21 (37.10) 6.92 (73.26)
Primary care (22, 19) 72.95 (29.78) 90.93 (29.83) (21, 21) 97.10 (53.71) 194.21 (107.41) 224.16 (60.67) 2103.28 (116.56)
Secondary care (25, 25) 994.64 (675.67) 1271.32 (709.81) (26, 26) 23.85 (11.28) 47.69 (22.57) 970.79 (662.38) 1223.63 (696.12)
Other health professionals (22, 21) 29.20 (14.23) 55.38 (23.54) (24, 24) 76.00 (63.91) 152.00 (127.81) 246.80 (68.18) 296.62 (138.59)
Social services (22, 22) 36.66 (20.98) 57.38 (39.79) (25, 25) 50.88 (28.17) 101.76 (56.34) 214.22 (35.92) 244.38 (70.75)
Other public services (24, 24) 2.17 (2.17) 4.33 (4.33) (24, 24) 3.25 (3.25) 6.50 (6.50) 21.08 (3.91) 22.17 (7.81)
Voluntary/charity services (19, 18) 94.16 (78.46) 169.87 (157.00) (23, 23) 264.75 (157.04) 529.50 (314.07) 2170.59 (187.19) 2359.63 (381.97)
OoP costs (24, 24) 54.30 (40.23) 108.61 (80.45) (22, 22) 9.60 (5.65) 19.20 (11.30) 44.71 (42.40) 89.41 (84.80)
Indirect costs (21, 20) 12773.14 (5514.18) 18311.10 (6403.21) (25, 25) 3738.70 (1327.96) 7477.40 (2655.92) 9034.44 (5247.63) 10833.70 (6439.61)
Total NHS-SS costsa (19, 17) 1067.82 (466.07) 1672.70 (590.99) (19, 19) 346.48 (188.56) 692.96 (377.12) 721.33 (502.77) 979.73 (686.19)
Total societal costsa (12, 10) 8884.28 (4030.08) 15909.84 (6448.88) (13, 13) 7272.38 (2362.56) 14544.76 (4725.11) 1611.90 (4583.11) 1365.07 (14544.76)
Imputed total NHS-SS costsb (26, 26) 1021.65 (400.94) 1725.04 (473.39) (26, 26) 348.28 (177.10) 696.56 (354.20) 673.38 (421.35) 1028.48 (581.28)
Imputed total societal costsb (26, 26) 16617.28 (7416.79) 22260.45 (7700.91) (26, 26) 5631.90 (1926.09) 11263.79 (3852.18) 10985.38 (7769.55) 10996.65 (8648.15)
Note: CBT = cognitive–behavioral therapy; NHS-SS = National Health Service and Social Services; OoP = out-of-pocket; SE = standard error; TAU = treatment as usual. NHS-SS costs include prescrip-
tion medicine, primary, secondary, other health care, and social services costs. Societal costs include all NHS-SS costs, plus other public services, voluntary/charity services, out-of-pocket, and indirect
costs.
a. Mean costs by expense category and totals across categories do not include multiple imputations for missing or incomplete resource use and cost information.
b. These total costs include multiple imputations (see methods section for more details of the imputation approach).
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Table 2 Mean Costs, Quality-Adjusted Life Years, and Cost Utility
Analysis
N Cost QALYs Unadjusted, Complete Case Analysis Imputed, Adjusted for Baseline Utility and Cost









































































































































Note: CBT = cognitive–behavioral therapy; CI = confidence interval; INB = incremental net (monetary) benefit; Inc = incremental; NHS-SS = National Health Service and Social Services cost perspective;
P(CE) = probability that CBT is cost-effective at a willingness-to-pay threshold of £30,000/QALY; PP-EVPI = per-person–expected value of perfect information; QALY = quality-adjusted life years;
Societal = societal cost perspective; TAU = treatment as usual.
a. Calculated using a willingness-to-pay threshold of £30,000.
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ranging from £4.9 million to £855 million.
Population EVPI estimates decreased for the major-
ity of the imputed/adjusted analyses, ranging from
£614,369 to £277 million.
For the 48-week, EQ-5D-3L, cost-utility analysis
from the societal perspective estimates of EVSI were
quite large, even at small sample sizes (Figure 3).
EVSI reached a maximum of £192,787,534 at a sample
size of 2,500, and remained relatively constant for all
larger sample sizes up to 5,000. The total cost of sam-
pling was much smaller than estimates of EVSI and
increased slightly for larger sample sizes. The ENGS
was therefore similar to the estimates of EVSI and
reached a maximum (£181,068,595) at a sample size
of 1,200 per arm. Any sample size greater than 10 was
associated with a positive return on investment.
DISCUSSION
Interpretation of Results
In the primary analysis CBT results in additional
costs of £6,647, with only 0.015 gain in QALYs,
leading to a negative INB estimate of £6,206 at a
WTP of £30,000 per QALY gained. From these
Figure 2 Cost-effectiveness acceptability curves. The cost-effectiveness acceptability curve represents the probability that CBT is cost-
effective given a threshold of X. There is between 3.00% to 49.70% and 0.86% to 36.00% probability that the ICER is below £30,000,
depending on the analytic perspective for the complete case and imputed/adjusted analyses respectively. NHS-SS = National Health
Service and Social Services; QALY = quality-adjusted life year.
Figure 3 The most efficient sample size for a future trial. The opti-
mal sample size per arm of a future trial is derived by first determin-
ing the expected value of sample information (EVSI) for a range of
sample sizes per arm and the associated cost of sampling. The differ-
ence between these values is the expected net gain of sampling
(ENGS). The sample size that maximizes the ENGS is the most effi-
cient sample size for the conduct of a future trial. ENGSn = expected
net gain of sampling for a given sample size n per arm; EVSIn =
expected value of sample information for a given sample size n per
arm; TCn = total cost of sampling for a given sample size n per arm.
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results, CBT is unlikely to be considered a cost-effec-
tive treatment, but analyses of uncertainty suggest a
23% probability of cost-effectiveness and population
EVPI of £277 million over a 5-year time horizon at a
WTP threshold of £30,000 per QALY gained, indicat-
ing that future research could be efficient to confirm
the cost-effectiveness of CBT. The most efficient
sample size of a confirmatory trial is likely to involve
1,200 participants per arm, but almost any positive
sample size has a positive return on investment. The
results of a number of additional analyses represent-
ing different analytic perspectives (NHS-SS and soci-
etal), different instruments for deriving health state
utility values (EQ-5D-3L and SF-6D), time horizons
(24, 48, and 72 weeks), and alternative approaches
for handling missing data also support the unlikely
cost-effectiveness of CBT, but indicate the potential
for cost-effectiveness over longer time horizons.
Policy Implications: Intervention Adoption and
Future Research Design
This pilot study was intended to inform the
design and potential efficiency of a future full-scale
randomized controlled trial (RCT) and so was not
powered to detect significant differences in out-
comes. It is therefore unsurprising that the out-
comes analysis did not detect such differences in
participants’ anxiety levels,4 and it would be
unwise to base a definitive policy decision on these
data. The INB point-estimate from the economic
evaluation conducted alongside the PAsSA trial
indicates that CBT is not cost-effective from the
societal perspective and resulted in additional costs
(£6,647) with only a small gain in QALYs (0.015).
Despite this, the majority of participants had posi-
tive views of the intervention with just over half
agreeing or strongly agreeing that CBT improved
their anxiety and 73% agreeing or strongly agreeing
that they would recommend therapy to others and
that it was helpful. This apparent paradox is likely
due to random noise from the small sample size. It
should, however, also be noted that our scenario
analyses suggest a potential improvement in cost-
effectiveness with a longer (72 weeks) time horizon
of analysis, especially for the EQ-5D-3L cost-utility
analysis from the NHS-SS perspective.
The relatively small sample size and prevalence
of missing data present further challenges to the
interpretation of the results. Due to the multidimen-
sional nature of data required for economic evalua-
tion, missing data are frequently an issue. Our
selected most appropriate analysis was derived
from only 15 complete case participants (6 CBT; 9
TAU) with the remaining 37 having one or more
components of data missing for costs and/or health
state utility values (Tables S5 and S6). Confidence
intervals in such scenarios will be very wide, poten-
tially rendering the point estimate INB uninforma-
tive. This is reflected in the ‘‘large’’ EVPI, suggesting
that future research could be a worthwhile invest-
ment, but all effort should be made to maximize the
completeness of data that are collected.
Our analysis has indicated that the most efficient
sample size of a full-scale RCT would be 1,200 par-
ticipants per arm, when ENGS reached a maximum
of £181,068,959. A future trial of this nature would
be quite large, possibly impractical to conduct and
traditional power calculations might indicate much
smaller sample sizes for a reasonably power study.
It should therefore be noted that even for small sam-
ple sizes (e.g., 50 participants per arm), although
not the most efficient, it would still result in rela-
tively large ENGS estimates (£73,522,457). This sig-
nifies that investment in full-scale trials much
smaller than the most efficient sample size identi-
fied in our analysis would still be worthwhile.
Comparison With Other Studies
There is limited evidence concerning the cost-
effectiveness of CBT in adults with AS experiencing
clinically significant anxiety, but there are two
studies that provide some evidence of the cost-
effectiveness of CBT in related populations.29,30 van
Steensel and others reported the cost-effectiveness
of individual CBT versus TAU for anxiety disorders
in children with ASD from a societal perspective in
the Netherlands.29 The study used a quasi-rando-
mized design to assign 49 children to either 15 ses-
sions of CBT or TAU with 6 months of follow-up.
Costs and QALYs were not statistically different
between the two interventions, although the point
estimate ICER suggested CBT dominated TAU. In
contrast, the point estimates of INB from the socie-
tal perspective in our study were relatively unfavor-
able for similar follow-up periods (i.e., 24 weeks;
Table 2, rows 3 and 4), as well as for longer follow-
up periods (48 weeks; Table 2, rows 7 and 8).
More recently, Visser and others developed a
probabilistic decision-analytic Markov model to
estimate the cost-effectiveness of group CBT com-
pared with a wait-list control for adult patients with
unexplained physical symptoms from a societal
DOBLE AND OTHERS
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perspective in the Netherlands over a 4-year time
horizon.30 RCT data from 162 patients were limited
to 3 months posttreatment but the patients receiving
group CBT were also followed to 6 months and 1
year in an uncontrolled phase. At 18 months group
CBT passed a threshold of e30,000/QALY; at 33
months it was dominant and remained dominant at
4 years. This indicates that longer time horizons
may be required for CBT to be cost-effective in our
analysis, which is apparent from the improved esti-
mates of cost-effectiveness in our scenario analyses
using a 72-week time horizon (Table S4).
Study Limitations
The analyses in our study were based on data
from a pilot RCT with crossover and were therefore
limited by a small sample size and limited follow-
up period. Due to the absence of prior data from the
literature concerning the effectiveness of CBT in an
AS population,2 it was not possible incorporate
additional sources of evidence into our analysis and
hence it was based solely on data from a pilot RCT.
This potentially complicates the interpretation of
the reported value of information estimates as these
figures are based on the assumptions that the pilot
study population would be the same as the popula-
tion to be included in a larger trial as well as the
same as the population for which we would want to
make treatment decisions in clinical practice.31
Furthermore, it is well known that pilot studies
may not be designed and conducted with the same
rigor as larger RCTs, potentially biasing the
results.32 Large amounts of missing data were also
observed for total social costs (27% to 42% of
patients missing total social costs depending on
time point and treatment allocation; Tables S5 and
S6), which are likely to be an important factor in
estimating the cost-effectiveness from the most
appropriate perspective. To account for these short-
comings, both complete-case and imputed/adjusted
analyses have been presented, with the results
remaining relatively consistent but associated with
considerable uncertainty.
Despite these weaknesses the analyses presented
are based on good research practices for cost-
effectiveness analyses alongside clinical trials9 and
conform to the good reporting practices for eco-
nomic evaluations.33 Due to the pilot nature of the
RCT data used in the analyses and therefore the
considerable uncertainty associated with the
results, a number of sensitivity analyses have been
conducted, all of which point to the general conclu-
sions of the unlikely cost-effectiveness of CBT over
short time horizons, but the potential for cost-
effectiveness over longer time horizons from the
NHS-SS perspective and to a lesser extent the socie-
tal perspective. Furthermore, the value in reducing
decision uncertainty and the most appropriate sam-
ple size for the conduct of a full-scale trial has also
been quantified. We have highlighted that there
may be value in reducing decision uncertainty
through the conduct of a larger trial with longer
term follow-up.
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